Neal E. Dunlap, M.D.

Chairman and Professor

Chairman and Professor

Dr. Neal E. Dunlap earned his medical degree from the University of Cincinnati College of Medicine.   He completed his internship at University of Cincinnati’s University Hospital, and his residency at the University of Virginia Medical Center in Charlottesville.  His clinical focus is primarily on multidisciplinary approaches to the treatment of lung cancer, esophageal cancer, head & neck cancers and liver cancers.  His research interests include the application of new treatment technologies in treatment of lung, liver, and head & neck malignancies in order to improve outcomes and reduce side effects.  He currently has investigator initiated trials open for the re-treatment of lung cancers after previous radiation, evaluation of early radiation-induced lung injury with 4-dimensional CT and the treatment of inoperable pancreatic cancer using radiosurgery.  He is currently the institutional principal investigator for multiple national cooperative group studies through NRG/RTOG in the treatment of lung and and head & neck cancers. He is member of the American Society for Radiation Oncology (ASTRO)


Institution and LocationDegreeDateField of Study
Paul Scherrer Institute Center for Proton Therapy6/2009-10/2009Proton Training
University of Virginia7/2007-6/2011Residency Radiation Oncology
University of Cincinnati7/2006-6/2007Internship Internal Medicine
University of CincinnatiM.D.8/2002-6/2006Doctor of Medicine
Wake Forest UniversityB.S.8/1996–5/2001Biology

Positions and Honors

Academic AppointmentsDate
Associate Clinical Director of the Multidisciplinary Head and Neck Cancer Program12/2013-present
Professor of Radiation Oncology, Department of Radiation Oncology, University of Louisville, Louisville, KY8/2011-present
Staff physician, Western State Hospital, Staunton, VA1/2009-6/2011

Other Experience and Professional Memberships



Honors and Awards

  • CLINICAL EXCELLENCE AWARD, University of Virginia Department of Radiation Oncology, 2010
    A faculty given award for recognizing clinical excellence amongst current residents
    Provided funding to train at the Paul Scherrer Institut, Center for Protons Radiotherapy, Villagen, Switzerland
    Competitive institutional GME-sponsored award based on academic achievement awarded to 12 recipients of a pool of 750 residents and fellows at UVA
    Recognizing clinical research accepted to the ASTRO Annual Meeting 2008, Boston MA
  • CLINICAL EXCELLENCE AWARD, University of Virginia Department of Radiation Oncology, 2008
    A faculty given award for recognizing clinical excellence amongst current residents

Selected peer-reviewed publications (in chronological order).

Mezera M, Chandrasekhar M, Kloecker G, Van Berkel V, Bousamra M, Dunlap NE:Stereotactic body radiation therapy as salvage for intrathoracic recurrence after definitive stereotactic body radiation therapy for early-stage lung cancer.Journal of Solid Tumors 2014:4(2):4-13.

Bhatt A, Goodwin N, Cash E, Bhatt G, Silverman C, Spanos W, Bumpous J, Potts K, Redman R, Allison W, Dunlap NE:Impact of Transcutaneous Neuromuscular Electrical Stimulation on dysphagia in head and neck cancer patients treated with definitive chemoradiation.Accepted to Head & Neck January 2014

Parks J, Kloecker G, Woo S, Dunlap NE:Stereotactic body radiation therapy for intrathoracic recurrence in patients with previously irradiated locally advanced non-small cell lung cancer.Accepted American Journal of Clinical Oncology December 18, 2013

Shaughnessy JN, Farghaly H, Wilson L, Redman R, Potts K, Bumpous J, Silverman C, Dunlap NE.:HPV: A factor in organ preservation for locally advanced larynx & hypopharynx cancer? Am J Otolaryngol. Accepted August 2013. Epub ahead of print

Harkenrider MM, Bertke MH, Dunlap NE: Stereotactic Body Radiation Therapy forUnbiopsied Early Stage Lung Cancer -A Multi-Institutional Analysis. Am J Clin Oncol 2013 May 8. Epub ahead of print.

Lee K, Kloecker G, Pan J, Rai S, Dunlap NE:The Integration of Multimodality Care for the Treatment of Small Cell Lung Cancer in a Rural Population and its Impact on Survival. Am J Clin Oncol 2013Sept 21. Epub ahead of print

Dunlap NE, Yang W, McIntosh A, Sheng K, Benedict SH, Read PW, Larner JM: Computed Tomography-Based Anatomic Assessment Overestimates Local Tumor Recurrence In Patients With Mass-like Consolidation After Stereotactic Body Radiation Therapy (SBRT) For Early Stage Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 1:84(5):1071-7. Epub 2012 Aug 14.

Cai J, Yue J, McLawhorn R,Yang W, Wijesooriya K, Dunlap NE, Sheng K, Yin F, and Benedict SH. Dosimetric comparison of 6 mv and 15 mv single arc rapidarc to helical tomotherapy for the treatment of pancreatic cancer. Med Dosimetry2011 Autumn;36(3):317-20

Dunlap NE, McIntosh A, Sheng K, Benedict SH, Turner AB, Shoushtari A, Sheehan J, Jones DR, Larner JM, Read PW. Helical Tomotherapy-based STAT SBRT: Dosimetric Evaluation for a Real Time SBRT Treatment Planning and Delivery Program. Med Dosimetry, 2010 Winter;35(4):312-9.

Dunlap NE,Woodford RL, Shoushtari AN, et al. Primary nasopharyngeal interdigitating dendritic cell tumor presentation and response to radiation therapy: case report and literature review. Rare Tumors. 2010;2(1):27-30.

Dunlap NE, Larner JM, Read PW, et al. Size Matters: A Comparison of T1 and T2 Peripheral Non-small Cell Lung Cancers Treated With Stereotactic Body Radiation Therapy (SBRT). JCTVS.2010 Sep;140(3):583-9.

McIntosh A, Dunlap NE, Sheng K, Geesy C, Turner B, Blackhall L, Weiss G, Lappinen E, Larner J, Read P. Helical TomoTherapy STAT-RT: Dosimetric evaluation for clinical implementation of a rapid palliation program. Med.Dosimetry. 2010 Winter;35(4):280-6.

Dunlap NE, Biedermann G, Yang W, Cai J, Sheng K, Benedict S, Kavanagh B, Larner J. Chest Wall Volume Receiving More Than 30 Gy Predicts Risk of Severe Pain and/or Rib Fracture After Lung SBRT. IntJRadiatOncolBiolPhys.2010, 76(3):796-801.

RingKL, YoungJL, DunlapNE, AndersenWA, SchneiderBF. Extended-field radiation therapy with whole pelvis radiotherapy and cisplatin chemosensitization in the treatment ofIB2-IIIB cervical carcinoma: a retrospective review. AmJObstetGynecol.2009 Apr 25.

Dunlap NE, Schwartz GG, et al., 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer. 2003 Aug 18;89(4):746-53.

Research Support

Ongoing Research Support

  1. RTOG 1021 (ACOSOG Z4099) A Randomized Phase III Study of Sublobar Resection (+/-Brachytherapy) versus Stereotactic Body Radiation therapy in High risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC), 3/15/2012 –12/31/2014, Principal Investigator.
  2. A Feasibility Study Using Four-Dimensional CT Imaging to Evaluate Lung Strain in Patients Treated with External Beam Radiation Therapy for Primary Lung Cancer, 6/30/2012 –7/1/2013, Principal Investigator.
  3. RTOG-0937: Randomized Phase II Study Comparing Phrophylactic Cranial Irradiation Along to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer, 10/31/2011 –12/31/201, Principal Investigator.
  4. RTOG-0839 –Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/-Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer, 5/1/2012 –12/31/2014, Principal Investigator.
  5. RTOG 0938 –12.0236. A Radomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer, 5/1/2012 –12/31/2014, Principal Investigator.
  6. Regional Lung Strain for Radiation Treatment Planning (R21 application), 9/1/2012 –8/31/2014, Co-Investigator.
  7. RTOG 0912 –11.0144 –A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer, Co-Investigator.
  8. RTOG 1016 –11.0365 –Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV –Associated Oropharynx Cancer, Co-Investigator.
  9. RTIG 0815 –12.0422 –A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer, Co-Investigator.
  10. RTOG 0534 –12.0423 -A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SUPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostectomy, Co-Investigator.
  11. Coulter Foundation Grant 2013 (pending application): Evaluating Radiation Injury In the Course of Radiation Treatment